GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial
Open Access
- 22 October 2025
- journal article
- clinical trial-protocol
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0335060
Abstract
Background: Glycemic control in type 1 diabetes (T1D) remains a challenge, with 20−30% of adults achieving an A1c target of 2 . Participants will be randomized in a 1:1 ratio to either tirzepatide with a target dosage of 5.0 mg (after titration) or standard of care (SoC) for 16 weeks. The primary endpoint is continuous glucose monitoring (CGM)-measured percent time spent between 3.9 and 10.0 mmol/L (TIR) from baseline to follow-up after 16 weeks of treatment. Secondary endpoints include: the CGM-measured change in 24/7 percent time >10.0 mmol/L, > 13.9 mmol/L, < 3.9 mmol/L, < 3.0 mmol/L. The exploratory endpoints include: the change in body mass index (BMI), liver steatosis (MASLD), and body composition. Safety outcomes include severe hypoglycemia, diabetic ketoacidosis (DKA), and refractory gastrointestinal side effects. Discussion: This is the first prospective study to investigate the safety and efficacy of tirzepatide (GIP/GLP1-RAs) as an adjuvant therapy to AID in T1D. This study may contribute unique data to significantly improving glucose and cardio-metabolic outcomes, re-directing attention to further treatment in T1D beyond insulin therapies.Keywords
Funding Information
- University of Bern (N/A)
- Dexcom (N/A)
This publication has 65 references indexed in Scilit:
- Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional studyDiabetologia, 2024
- Overweight and Obesity in People Living With Type 1 Diabetes: A Cross‐Sectional Analysis of the BETTER RegistryDiabetes/Metabolism Research and Reviews, 2024
- Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapyDiabetologia, 2023
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysisDiabetologia, 2022
- The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2021
- Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity2020
- Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastographyJournal of Magnetic Resonance Imaging, 2019
- Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010JAMA, 2015
- Time trends in mortality rates in type 1 diabetes from 2002 to 2011Diabetologia, 2013
- Dynamic balancing randomization in controlled clinical trialsStatistics in Medicine, 2005